Monobasic Sodium Phosphate And Dibasic Sodium Phosphate

Constipation, Gastroenteritis, Electrolyte imbalance + 27 more
Treatment
6 FDA approvals
20 Active Studies for Monobasic Sodium Phosphate And Dibasic Sodium Phosphate

What is Monobasic Sodium Phosphate And Dibasic Sodium Phosphate

Sodium phosphate, monobasicThe Generic name of this drug
Treatment SummarySodium phosphate is a laxative that helps stimulate bowel movements. It works by increasing fluid in the small intestine, typically resulting in a bowel movement within 30 minutes to 6 hours.
K Phos Neutralis the brand name
Monobasic Sodium Phosphate And Dibasic Sodium Phosphate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
K Phos Neutral
Sodium phosphate, monobasic
1977
124

Approved as Treatment by the FDA

Sodium phosphate, monobasic, otherwise known as K Phos Neutral, is approved by the FDA for 6 uses including Hypophosphatemia and Bowel preparation therapy .
Hypophosphatemia
Bowel preparation therapy
Renal Replacement Therapy
Parenteral Nutrition, Total
Hypophosphatemia
Hypophosphatemia

Effectiveness

How Monobasic Sodium Phosphate And Dibasic Sodium Phosphate Affects PatientsSodium phosphate helps make stool softer and move more quickly through the large intestine.
How Monobasic Sodium Phosphate And Dibasic Sodium Phosphate works in the bodySodium phosphate is thought to work by making the intestine more watery, which helps stools become softer and pass more easily.

When to interrupt dosage

The quantity of Monobasic Sodium Phosphate And Dibasic Sodium Phosphate is contingent upon the determined condition, including fluid and electrolyte maintenance therapy, Fluid replacement therapy and Irrigation. The extent of dosage contrasts as per the delivery technique (e.g. Liquid or Tablet, coated) delineated in the accompanying table.
Condition
Dosage
Administration
Bowel preparation therapy
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
postoperative fluid imbalance
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
sigmoidoscopy
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
proctoscopy
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Management Audit
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Acid-Base Imbalance
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Gastroenteritis
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Parenteral Nutrition, Total
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Red Blood Cell Count measurement
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Colonoscopy
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Electrolyte replacement therapy
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
intraocular surgery
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
postoperative electrolyte imbalance
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Hypophosphatemia
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Electrolyte imbalance
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Acidosis
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Constipation
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Hypophosphatemia
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Irrigation
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous
Electrolyte replacement
, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL
, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Warnings

Monobasic Sodium Phosphate And Dibasic Sodium Phosphate has four contraindications and should not be consumed when experiencing the conditions specified in the following table.Monobasic Sodium Phosphate And Dibasic Sodium Phosphate Contraindications
Condition
Risk Level
Notes
biopsy-proven acute phosphate nephropathy
Do Not Combine
Hypernatremia
Do Not Combine
calcium
Do Not Combine
high phosphate levels
Do Not Combine
There are 20 known major drug interactions with Monobasic Sodium Phosphate And Dibasic Sodium Phosphate.
Common Monobasic Sodium Phosphate And Dibasic Sodium Phosphate Drug Interactions
Drug Name
Risk Level
Description
Alloin
Minor
The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Alloin.
Carboxymethylcellulose
Minor
The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Carboxymethylcellulose.
Castor oil
Minor
The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Castor oil.
Chlorpropamide
Minor
Sodium phosphate, monobasic may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
Deacetylbisacodyl
Minor
The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Deacetylbisacodyl.
Monobasic Sodium Phosphate And Dibasic Sodium Phosphate Toxicity & Overdose RiskThe highest toxic dose of sodium phosphate found in rats is 250mg/kg when injected and 8290mg/kg when taken orally. High levels of phosphate can cause symptoms such as muscle spasms, dehydration, low blood pressure, rapid heartbeat, high fever, and unconsciousness. Smaller patients may be at higher risk for developing phosphate toxicity.

Monobasic Sodium Phosphate And Dibasic Sodium Phosphate Novel Uses: Which Conditions Have a Clinical Trial Featuring Monobasic Sodium Phosphate And Dibasic Sodium Phosphate?

54 active studies are in progress to assess the utility of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate for Electrolyte replenishment, proctoscopy and Irrigation.
Condition
Clinical Trials
Trial Phases
Electrolyte replacement
0 Actively Recruiting
Fluid replacement therapy
0 Actively Recruiting
Renal Replacement Therapy
1 Actively Recruiting
Phase 3
postoperative electrolyte imbalance
0 Actively Recruiting
proctoscopy
0 Actively Recruiting
Hypophosphatemia
1 Actively Recruiting
Phase 2
Colonoscopy
3 Actively Recruiting
Not Applicable
fluid and electrolyte maintenance therapy
0 Actively Recruiting
Electrolyte imbalance
0 Actively Recruiting
Bowel preparation therapy
1 Actively Recruiting
Phase 1, Phase 2
Electrolyte replacement therapy
0 Actively Recruiting
postoperative fluid imbalance
0 Actively Recruiting
Gastroenteritis
12 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1
Irrigation
0 Actively Recruiting
Red Blood Cell Count measurement
0 Actively Recruiting
Parenteral Nutrition
0 Actively Recruiting
Metabolic acidosis
0 Actively Recruiting
sigmoidoscopy
0 Actively Recruiting
Rehydration
0 Actively Recruiting
Constipation
18 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 3, Phase 1

Patient Q&A Section about monobasic sodium phosphate and dibasic sodium phosphate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between monobasic and dibasic potassium phosphate?

"Monobasic and dibasic refers to the number of potassium cations bound to the phosphate molecule. KH2PO4 is monobasic and can release a low amount of potassium, whereas K2HPO4 is dibasic and can release a high amount of potassium when used in fertilizer."

Answered by AI

What does dibasic sodium phosphate do?

"Sodium Phosphate Dibasic is a white powder that is odorless and has a sand-like texture. It is used to create starch, as well as an emulsifier in various foods. Additionally, it is involved in the production of enamels, ceramics and detergents."

Answered by AI

What is meant by monobasic sodium phosphate?

"Monosodium phosphate is a salt composed of sodium and dihydrogen phosphate. It is a common industrial chemical that exists in an anhydrous form, as well as mono- and dihydrates."

Answered by AI

Clinical Trials for Monobasic Sodium Phosphate And Dibasic Sodium Phosphate

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA
While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.
Phase < 1
Waitlist Available
Stanford Digestive Health Clinic (+1 Sites)Sean P Spencer, MD, PhD
Image of Center for Nutraceutical and Dietary Supplement Research in Memphis, United States.

Inno Cleanse for Abdominal Bloating

18+
All Sexes
Memphis, TN
The purpose of the present study is to investigate the impact of a natural dietary supplement, Inno Cleanseâ„¢, to reduce bloating in a population of otherwise healthy men and women, who claim to feel frequently bloated. Inno CleanseTM dietary supplement is manufactured in the United States under current Good Manufacturing Practices (cGMP) and is marketed by InnoSupps as a digestive health aid. It is sold in the United States on the company's website, Amazon, and in many large retail outlets. It remains a very popular product, with close to 1.4 million units sold since 2020, with a reported 66,000 units sold in the past three months. Despite the prevalence of dietary supplements identifying as digestive aids, detoxification, and cleanses, very little research has been done to determine their effectiveness. The product appears to be well-designed, with multiple ingredients included which have scientific evidence of effectiveness. That said, and despite the overall positive reviews, there is no known clinical research to support the product's effectiveness. Therefore, the aim of this study is to evaluate the efficacy of the Inno Cleanse product to reduce bloating and result in other positive outcomes (weight loss). This study will be run as a double-blind placebo-controlled trial, in which subjects will use the product or placebo for two weeks. It is hypothesized that treatment with the dietary supplement Inno Cleanse will result in reduced bloating, as evidenced by self-reported reductions in bloating and hunger, as well as moderate weight loss and a reduction in body circumference measures due to the reduced bloating. In addition, multiple anecdotal reports of improved skin health have been noted in those using the product. Additionally, routine blood and urine sample analysis will be performed as a secondary outcome, as a safety measure.
Recruiting
Paid Trial
Center for Nutraceutical and Dietary Supplement ResearchRichard Bloomer, PhD
Have you considered Monobasic Sodium Phosphate And Dibasic Sodium Phosphate clinical trials? We made a collection of clinical trials featuring Monobasic Sodium Phosphate And Dibasic Sodium Phosphate, we think they might fit your search criteria.Go to Trials
Image of Banner - University Medical Center South in Tucson, United States.

Dexmedetomidine + Dexamethasone for Postoperative Pain

18 - 75
All Sexes
Tucson, AZ
The goal of this clinical study is to improve upon the standard practice of utilizing nerve blocks to enhance the satisfaction of patients undergoing shoulder, or foot and ankle surgery regarding their quality of pain control, the duration of their nerve blocks, as well as the avoidance of opioid medications and subsequently their undesirable side effects. The researchers hypothesize that dexmedetomidine and dexamethasone (Dex-Dex) will work synergistically as adjuncts in a low, non-weight based formula. This would allow the investigators to improve patient satisfaction by providing them with a superior means of pain control that is longer in duration with a decreased probability of unwanted side effects. The proposed clinical study will be a prospective, randomized control trial.
Phase 1 & 2
Waitlist Available
Banner - University Medical Center SouthRonald Tang, MD
Have you considered Monobasic Sodium Phosphate And Dibasic Sodium Phosphate clinical trials? We made a collection of clinical trials featuring Monobasic Sodium Phosphate And Dibasic Sodium Phosphate, we think they might fit your search criteria.Go to Trials
Image of Mercy Hospital in Pittsburgh, United States.

Autologous Fat-Based Therapy for Scar Tissue

18+
All Sexes
Pittsburgh, PA
The goal of this study is to explore if an adipose-based therapeutic strategy can treat contracted scars secondary to soft-tissue burn wounds in injured individuals, especially those with severe burns or soft-tissue loss. The main question it aims to answer are: \- Can autologous layered composite grafting demonstrate non-inferiority compared to full-thickness skin grafting for delayed reconstruction of post-burn or trauma scar contracture? Researchers will compare the single-stage autologous layered composite grafting method to traditional methods to see if it improves healing outcomes, minimizes scarring, and reduces infection risk. Participants will: * Receive fat grafting at time of scar revision. * Undergo simultaneous split-thickness skin grafting for full soft-tissue reconstruction.
Waitlist Available
Has No Placebo
Mercy Hospital (+1 Sites)Francesco Egro
Image of Hamilton Health Sciences in Hamilton, Canada.

Kiwifruit Extract for Constipation in Children

4 - 17
All Sexes
Hamilton, Canada
The goal of this pilot feasibility randomized controlled trial is to determine whether Actazin (kiwifruit extract) is a feasible and effective alternative to polyethylene glycol 3350 (PEG 3350) for maintenance therapy in children with functional constipation (FC). This study will include children aged 4 to 17 years who meet the Rome IV criteria for functional constipation. The main questions it aims to answer are: 1. Is it feasible to conduct a definitive, multi-centre trial comparing Actazin to PEG 3350 in children with FC? 2. What are the within-group differences in clinical outcomes such as stool frequency, abdominal pain, and laxative use over a 4-week period? Researchers will compare chewable Actazin tablets with placebo PEG 3350 powder to PEG 3350 powder with placebo Actazin tablets to see if Actazin is a viable non-pharmacologic natural health product alternative for treating FC. Participants will: Undergo an initial bowel cleanout using PEG 3350 and bisacodyl. Following, they will be randomized to one of two groups: 1. Actazin chewable tablets (titrate to effect: 600-2400 mg/day) + placebo PEG 3350 2. PEG 3350 (dose based on age and titratable to effect) + placebo Actazin chewable tablets Participants will take the assigned intervention daily for 4 weeks and complete a daily bowel diary recording stool frequency, consistency (Bristol Stool Scale), abdominal pain, and laxative use. They will have weekly follow-ups via phone or electronic survey to assess adherence, medication use, and adverse events. Additionally, a bi-weekly follow-up will be conducted for an additional 8 weeks to track longer-term outcomes. Outcomes: Primary feasibility outcomes include consent rate, adherence to allocated intervention, and 4-week follow-up completion rate. Secondary clinical outcomes include resolution of FC (Rome IV criteria), weekly stool frequency, abdominal pain episodes, use of rescue laxatives, and treatment palatability. This study is being conducted at McMaster Children's Hospital and is funded by the Hamilton Academic Health Sciences Organization (HAHSO). Data collection will be managed using the Lumediâ„¢ platform, and safety will be overseen by a Data Safety Monitoring Board (DSMB).
Phase 2 & 3
Waitlist Available
Hamilton Health SciencesMohamed M Eltorki, MBChB, MSc
Have you considered Monobasic Sodium Phosphate And Dibasic Sodium Phosphate clinical trials? We made a collection of clinical trials featuring Monobasic Sodium Phosphate And Dibasic Sodium Phosphate, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security